AR-V7 and prostate cancer: The watershed for treatment selection?

被引：49

作者：

Ciccarese, Chiara ^{[1
]}

Santoni, Matteo ^{[2
]}

Brunelli, Matteo ^{[3
]}

Buti, Sebastiano ^{[4
]}

Modena, Alessandra ^{[1
]}

Nabissi, Massimo ^{[5
]}

Artibani, Walter ^{[6
]}

Martignoni, Guido ^{[3
]}

Montironi, Rodolfo ^{[7
]}

Tortora, Giampaolo ^{[1
]}

Massari, Francesco ^{[1
]}

机构：

[1] Univ Verona, Azienda Osped Univ Integrata, Med Oncol, Ple LA Scuro 10, I-37100 Verona, Italy

[2] Univ Marche Reg, Med Oncol, AOU Osped Riuniti, Polytech, Ancona, Italy

[3] Univ Verona, AOUI, Dept Pathol & Diagnost, I-37100 Verona, Italy

[4] Univ Hosp Parma, Med Oncol Unit, Parma, Italy

[5] Univ Camerino, Sch Pharm, Expt Med Sect, I-62032 Camerino, Italy

[6] Univ Verona, Azienda Osped Univ Integrata, Urol Clin, Dept Oncol & Surg Sci, I-37100 Verona, Italy

[7] Polytech Univ Marche Reg, Sch Med, AOU Osped Riuniti, Sect Pathol Anat, Ancona, Italy

来源：

CANCER TREATMENT REVIEWS | 2016年 / 43卷

关键词：

Prostate cancer; Androgen receptor; Splice variant; AR-V7; Prognostic role; Anti-androgens sensitivity; Taxane sensitivity; ANDROGEN RECEPTOR-ACTIVITY; SPLICE VARIANTS; DNA-BINDING; INCREASED SURVIVAL; STEROID-BINDING; SMALL-MOLECULE; HINGE REGION; TARGET GENES; RESISTANT; ENZALUTAMIDE;

D O I：

10.1016/j.ctrv.2015.12.003

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The androgen receptor (AR) plays a key role in progression to metastatic castration-resistant prostate cancer (mCRPC). Despite the recent progress in targeting persistent AR activity with the next generation hormonal therapies (abiraterone acetate and enzalutamide), resistance to these agents limits therapeutic efficacy for many patients. Several explanations for response and/or resistance to abiraterone acetate and enzalutamide are emerging, but growing interest is focusing on importance of AR splice variants (AR-Vs) and in particular of AR-V7. Increasing evidences highlight the concept that variant expression could be used as a potential predictive biomarker and a therapeutic target in advanced prostate cancer. Therefore, understanding the mechanisms of treatment resistance or sensitivity can help to achieve a more effective management of mCRPC, increasing clinical outcomes and representing a promising and engaging area of prostate cancer research. (C) 2015 Elsevier Ltd. All rights reserved.

引用

页码：27 / 35

页数：9

共 87 条

[61] Constitutively Active AR-V7 Plays an Essential Role in the Development and Progression of Castration-Resistant Prostate Cancer
Qu, Yuanyuan
Dai, Bo
Ye, Dingwei
Kong, Yunyi
Chang, Kun
Jia, Zhongwei
Yang, Xiaoqun
Zhang, Hailiang
Zhu, Yao
Shi, Guohai
[J]. SCIENTIFIC REPORTS, 2015, 5
[62] Phase I Study of ARN-509, a Novel Antiandrogen, in the Treatment of Castration-Resistant Prostate Cancer
Rathkopf, Dana E.
Morris, Michael J.
Fox, Josef J.
Danila, Daniel C.
Slovin, Susan F.
Hager, Jeffrey H.
Rix, Peter J.
Maneval, Edna Chow
Chen, Isan
Goenen, Mithat
Fleisher, Martin
Larson, Steven M.
Sawyers, Charles L.
Scher, Howard I.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (28) : 3525 - +
[63] Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Ryan, Charles J.
Smith, Matthew R.
de Bono, Johann S.
Molina, Arturo
Logothetis, Christopher J.
de Souza, Paul
Fizazi, Karim
Mainwaring, Paul
Piulats, Josep M.
Ng, Siobhan
Carles, Joan
Mulders, Peter F. A.
Basch, Ethan
Small, Eric J.
Saad, Fred
Schrijvers, Dirk
Van Poppel, Hendrik
Mukherjee, Som D.
Suttmann, Henrik
Gerritsen, Winald R.
Flaig, Thomas W.
George, Daniel J.
Yu, Evan Y.
Efstathiou, Eleni
Pantuck, Allan
Winquist, Eric
Higano, Celestia S.
Taplin, Mary-Ellen
Park, Youn
Kheoh, Thian
Griffin, Thomas
Scher, Howard I.
Rathkopf, Dana E.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (02) : 138 - 148
[64] Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, Howard I.
Fizazi, Karim
Saad, Fred
Taplin, Mary-Ellen
Sternberg, Cora N.
Miller, Kurt
de Wit, Ronald
Mulders, Peter
Chi, Kim N.
Shore, Neal D.
Armstrong, Andrew J.
Flaig, Thomas W.
Flechon, Aude
Mainwaring, Paul
Fleming, Mark
Hainsworth, John D.
Hirmand, Mohammad
Selby, Bryan
Seely, Lynn
de Bono, Johann S.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (13) : 1187 - 1197
[65] Differential DNA binding by the androgen and glucocorticoid receptors involves the second Zn-finger and a C-terminal extension of the DNA-binding domains
Schoenmakers, E
Alen, P
Verrijdt, G
Peeters, B
Verhoeven, G
Rombauts, W
Claessens, F
[J]. BIOCHEMICAL JOURNAL, 1999, 341 : 515 - 521
[66] The Influence of Prior Abiraterone Treatment on the Clinical Activity of Docetaxel in Men with Metastatic Castration-resistant Prostate Cancer
Schweizer, Michael T.
Zhou, Xian C.
Wang, Hao
Bassi, Sunakshi
Carducci, Michael A.
Eisenberger, Mario A.
Antonarakis, Emmanuel S.
[J]. EUROPEAN UROLOGY, 2014, 66 (04) : 646 - 652
[67] Formation of the androgen receptor transcription complex
Shang, YF
Myers, M
Brown, M
[J]. MOLECULAR CELL, 2002, 9 (03) : 601 - 610
[68] Steinestel J, 2015, ONCOTARGET
[69] Androgen Receptor Splice Variant AR3 Promotes Prostate Cancer via Modulating Expression of Autocrine/Paracrine Factors
Sun, Feng
Chen, He-ge
Li, Wei
Yang, Xi
Wang, Xin
Jiang, Richeng
Guo, Zhiyong
Chen, Hegang
Huang, Jiaoti
Borowsky, Alexander D.
Qiu, Yun
[J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2014, 289 (03) : 1529 - 1539
[70] Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant
Sun, Shihua
Sprenger, Cynthia C. T.
Vessella, Robert L.
Haugk, Kathleen
Soriano, Kathryn
Mostaghel, Elahe A.
Page, Stephanie T.
Coleman, Ilsa M.
Nguyen, Holly M.
Sun, Huiying
Nelson, Peter S.
Plymate, Stephen R.
[J]. JOURNAL OF CLINICAL INVESTIGATION, 2010, 120 (08) : 2715 - 2730

← 1 2 3 4 5 6 7 8 9 →